Загрузка...
The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
BACKGROUND/AIM: Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinib-induced JAK/STAT pathway inhibition i...
Сохранить в:
| Опубликовано в: : | Turk J Med Sci |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
The Scientific and Technological Research Council of Turkey
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7018380/ https://ncbi.nlm.nih.gov/pubmed/30997981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3906/sag-1807-152 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|